Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Diabetic neuropathy: a study on the effects of insulin resistance on its pathophysiology and a randomized clinical trial to prevent neural loss

Project description

Advancing understanding of diabetic neuropathy

Diabetic neuropathy is a type of nerve damage caused by prolonged high blood sugar levels in individuals with diabetes. It often leads to symptoms such as pain, tingling and numbness in the extremities, which can significantly affect quality of life and mobility. With type 2 diabetes reaching epidemic proportions, the EU-funded SenseDiabetes project seeks to raise awareness about diabetic neuropathy and improve early detection. Efforts will focus on advancing our understanding of the condition by examining insulin resistance in individuals with diabetes with and without neuropathy. Researchers will evaluate the effectiveness of two different drugs in treating early diabetic neuropathy and investigate their impact on nerve density and function.

Objective

We are facing a global epidemic of type 2 diabetes (T2D). Diabetic neuropathy (DN) is the most common complication of T2D affecting ~50% of patients with T2D. If not diagnosed early, DN may lead to further catastrophic complications. However, despite its potentially huge impact on patients’ quality of life, and burden imposed on healthcare systems, patients with T2D and practitioners are often unaware of the manifestations of DN. To make things worse, currently there are no approved treatments for DN.
SenseDiabetes has several aims. First, we wish to increase our knowledge regarding the pathophysiology of DN, specifically assessing whether patients with T2D and DN have worse insulin resistance compared to patients with T2D without DN. While previous studies on DN have shown an effect of insulin resistance on DN, poor indexes of insulin resistance have been used. In SenseDiabetes we will use for the first time the gold standard method for the assessment of insulin resistance, i.e. the euglycemic insulin clamp. Second, we will assess the efficacy of two commonly used antidiabetic drugs in early DN. Patients with T2D and early signs of DN will be randomized to receive treatment for 9 months with either Semaglutide or Empagliflozin. The effects of these drugs on DN outcomes (small fiber density, cardiovascular autonomic function) and advanced glycation end-products will be assessed. Further, we will study with ex vivo experiments the effects of the two drugs of peripheral nerve density (obtained with skin biopsies), and in in vitro experiments we will study the exact mechanisms of action of Semaglutide on cultures of peripheral nerves. Along with the scientific part, SenseDiabetes has a dedicated WP to increase awareness of DN.SenseDiabetes may thus be pivotal for the development of new strategies to combat DN. Also, SenseDiabetes aims to promote awareness of DN and thus increase societal impact through early recognition of DN and prevention of further complications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2023-TALENTS-02

See all projects funded under this call

Coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Net EU contribution
€ 153 486,72
Address
6 CHRISTOU LADA STR
105 61 ATHINA
Greece
Region
Αττική Aττική Κεντρικός Τομέας Αθηνών
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data